$3.05
0.093.04%
At close: Nov 13, 4:00 PM EST
$3.04
-0.0079-0.26%
After Hours: 5:49 PM EST
Protalix BioTherapeutics Inc
PLXAMEX
Protalix BioTherapeutics rose 53.4% from $1.93 to $2.96, ahead of the S&P 500's +12.3%. Its worst day was Mar 18 (−20.8%), and its low came Dec 3 at $1.72.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.03 missed the $0.05 estimate on $17.7M revenue (est. $17.9M).
0.0% · S&P 500 −1.7%
Protalix BioTherapeutics closed at its lowest level of the year, 10.9% below where the year started.
Story events cover the past 12 months · Times ET
−3.4% · S&P 500 +0.1%
Protalix BioTherapeutics shares rose 12.4%, while the S&P 500 fell 0.0%.
+12.4%, on 4M shares, the year's heaviest volume · S&P 500 0.0%
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026If approved by
+13.0%, the year's best day · S&P 500 −0.3%
Protalix BioTherapeutics closed at its highest level of the year, 63.2% above where the year started.
+5.7% · S&P 500 −0.3%
European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks to every-four-weeks
+9.9% · S&P 500 +0.9%
EPS of $-0.06 missed the $0.01 estimate on $9.3M revenue (est. $14.4M); FY revenue guidance of $78.0M–$83.0M against the $71.8M consensus.
−20.8%, the year's worst day · S&P 500 −1.4%
EPS of $0.22 beat the $-0.01 estimate on $33.8M revenue (est. $11.5M); FY revenue guidance of $78.0M–$83.0M against the $79.1M consensus.
+1.0% · S&P 500 +0.6%
EPS of $0.05 beat the $-0.01 estimate on $19.9M revenue (est. $12.9M); FY revenue guidance of $78.0M–$83.0M against the $78.3M consensus.
+7.8% · S&P 500 +0.3%
EPS of $0.05 beat the $-0.02 estimate on $21.8M revenue (est. $12.3M); FY revenue guidance of $78.0M–$83.0M against the $71.4M consensus.
+11.3% · S&P 500 −0.4%
Where it ended: a close of $2.96 on Nov 12, 2026.
Nothing in the past 12 months.
All PLX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PLX and SPY from Benzinga historical bars. Not investment advice.
